Stage IV Ovarian Cancer Withdrawn Phase 1 Trials for Muromonab (DB00075)

IndicationStatusPhase
DBCOND0030167 (Stage IV Ovarian Cancer)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02470559Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or RecurrentTreatment